Portfolio company
Emergence
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
This biopharmaceutical company develops antibody drug conjugates to treat high-need cancers including bladder and triple-negative breast cancer.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Emergence Therapeutics
This biopharmaceutical company develops antibody-drug conjugate immunotherapies to treat solid tumours for patients with high unmet medical needs.
Adcendo
This clinical-stage biotechnology company develops antibody-drug conjugates to treat patients with various types of cancer and high unmet medical needs.
Adcytherix
This biopharmaceutical company develops novel antibody-drug conjugates to treat various forms of cancer for patients with high unmet clinical needs.
TORL BioTherapeutics
This biopharmaceutical company develops antibody-drug conjugates and monoclonal antibodies to treat various cancers for patients with unmet medical needs.
Clinical stage immunotherapy company
This company develops next-generation antibody-drug conjugates to treat patients with solid tumor malignancies.
Adcendo ApS
The company develops antibody-drug conjugates to treat patients with advanced solid tumors and cancers that have high unmet medical needs.
Profound Bio
This clinical-stage biotechnology company develops antibody-drug conjugates and targeted therapies for patients with solid tumors and hematological malignancies.
Rainier Therapeutics
The company develops targeted antibody therapies for patients with early-stage and metastatic bladder cancer.